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Prostate cancer is the leading cancer in American males, and the third leading cause of cancer 
deaths among men of all ages. While common, it is generally a slow-growing disease and active 
surveillance or primary treatments - including surgery, radiation or hormone ablation - are sufficient 
for the majority of patients. However, development of castration-resistant prostate cancer (CRPC) is 
generally lethal and treatment options remain limited. 
A novel drug, abiraterone, has recently been FDA-approved for men with CRPC. Abiraterone 
functions to block a key enzyme, CYP17A1, involved in steroidogenesis of androgens. Abiraterone 
treatment decreases circulating levels of testosterone and related androgens, which are important 
regulators of prostate cancer growth. While abiraterone has been associated with impressive 
responses in many men with CRPC, the duration of effect has been variable. Ultimately, most men 
will progress. The effects of abiraterone on prostate-tissue androgen levels and the mechanisms of 
resistance to abiraterone are not well characterized. To address these issues, Dr. Elahe Mostaghel 
of the Clinical Research Division and her collaborators treated mice bearing human CRPC 
xenografts with abiraterone to assess the effects on tumor growth, androgen concentrations, AR 
expression and steroidogenic gene expression. 
Initial treatment of two different CRPC xenograft models resulted in tumor suppression and 
increased survival. Following initiation of abiraterone treatment, a rapid decrease in serum PSA and 
tumor-specific androgens was observed, leading to slower tumor growth and a survival advantage. 
However, extended abiraterone treatment activated multiple pathways to preserve AR-mediated 
gene expression in tumors. These pathways include increased expression of full length androgen 
receptor and ligand-independent splice variants that are constitutively active, as well as altering 
genes involved in steroid biosynthesis. As a result, dihydrotestosterone, the most potent form of the 
male androgens, is synthesized from adrenal androgens and its catabolism is impaired. Thus, while 
CYP17A1 inhibition suppresses tissue androgens and tumor growth, low-level androgens remain  
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present, combined with elevated AR expression, to maintain sensitivity to low androgen levels. 
Overall, this study identifies mechanisms by which prostate tumors become resistant to abiraterone, 
and suggests that treatment of patients with higher dose levels of abiraterone, or potent AR 
blockade in combination with CYP17A1 inhibition may be of clinical benefit. 
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